Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial

Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial

Summary: Despite the similar clinical outcomes after renin-angiotensin system (RAS) inhibitor (RASi) continuation or withdrawal in COVID-19, the effects on angiotensin-converting enzyme 2 (ACE2) and RAS metabolites remain unclear. In a substudy of the randomized controlled Austrian Corona Virus Adap...

Full description

Bibliographic Details
Main Authors: Vincent Rathkolb, Marianna T. Traugott, Andreas Heinzel, Marko Poglitsch, Judith Aberle, Farsad Eskandary, Agnes Abrahamowicz, Martin Mueller, Petra Knollmueller, Tarik Shoumariyeh, Jasmin Stuflesser, Ivan Seeber, Georg Gibas, Hannah Mayfurth, Viktoria Tinhof, Lukas Schmoelz, Markus Zeitlinger, Christian Schoergenhofer, Bernd Jilma, Bernd Genser, Wolfgang Hoepler, Sara Omid, Mario Karolyi, Christoph Wenisch, Rainer Oberbauer, Alexander Zoufaly, Manfred Hecking, Roman Reindl-Schwaighofer
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:iScience
Subjects:
Virology
Human metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S258900422302223X

Internet

http://www.sciencedirect.com/science/article/pii/S258900422302223X

Similar Items